Sunshine Lake Pharma Co., Ltd. (HKG:6887)
Hong Kong
· Delayed Price · Currency is HKD 41.80
+0.48 (1.16%)
At close: Apr 29, 2026
Sunshine Lake Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 4,815 | 3,724 | 6,295 | 3,745 | 913.79 | Upgrade
|
| Revenue Growth (YoY) | 29.31% | -40.84% | 68.08% | 309.83% | -61.08% | Upgrade
|
| Cost of Revenue | 1,130 | 929.73 | 1,309 | 898.88 | 430.09 | Upgrade
|
| Gross Profit | 3,685 | 2,794 | 4,986 | 2,846 | 483.7 | Upgrade
|
| Selling, General & Admin | 2,571 | 1,539 | 1,933 | 1,555 | 880.07 | Upgrade
|
| Research & Development | 648.69 | 493.44 | 192.29 | 129.61 | 109.67 | Upgrade
|
| Other Operating Expenses | -153.12 | -26.25 | 63.83 | 842.69 | -51.11 | Upgrade
|
| Operating Expenses | 2,994 | 2,125 | 2,196 | 2,523 | 941.81 | Upgrade
|
| Operating Income | 691.16 | 668.96 | 2,790 | 322.72 | -458.11 | Upgrade
|
| Interest Expense | -230.2 | -97.53 | -227.4 | -281.65 | -243.81 | Upgrade
|
| Interest & Investment Income | 38.75 | 78.69 | 62.42 | 6.74 | 11.35 | Upgrade
|
| Earnings From Equity Investments | 0.05 | 0.29 | -0.03 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.1 | 4.79 | -16.86 | -241.43 | 49.2 | Upgrade
|
| EBT Excluding Unusual Items | 499.85 | 655.21 | 2,608 | -193.62 | -641.37 | Upgrade
|
| Impairment of Goodwill | - | - | - | -75.9 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 10.59 | -1.79 | 4.39 | 522.7 | 19.24 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.08 | 10.33 | -0.53 | -0.82 | -19.07 | Upgrade
|
| Asset Writedown | -67.8 | -86.52 | -485.39 | -212.94 | -25.98 | Upgrade
|
| Pretax Income | 439.56 | 577.23 | 2,127 | 39.42 | -667.18 | Upgrade
|
| Income Tax Expense | 169.53 | 94.52 | 270.95 | -9.82 | -79.46 | Upgrade
|
| Earnings From Continuing Operations | 270.03 | 482.71 | 1,856 | 49.24 | -587.72 | Upgrade
|
| Minority Interest in Earnings | 2.41 | - | 136.8 | 27.36 | 0.08 | Upgrade
|
| Net Income | 272.44 | 482.71 | 1,993 | 76.6 | -587.65 | Upgrade
|
| Net Income to Common | 272.44 | 482.71 | 1,993 | 76.6 | -587.65 | Upgrade
|
| Net Income Growth | -43.56% | -75.78% | 2501.24% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 488 | 232 | 232 | 232 | 232 | Upgrade
|
| Shares Outstanding (Diluted) | 498 | 232 | 232 | 232 | 232 | Upgrade
|
| Shares Change (YoY) | 114.82% | - | - | - | -20.42% | Upgrade
|
| EPS (Basic) | 0.56 | 2.08 | 8.59 | 0.33 | -2.53 | Upgrade
|
| EPS (Diluted) | 0.55 | 2.08 | 8.57 | 0.33 | -2.54 | Upgrade
|
| EPS Growth | -73.57% | -75.73% | 2496.14% | - | - | Upgrade
|
| Free Cash Flow | - | -878.89 | 1,329 | 1,130 | -1,019 | Upgrade
|
| Free Cash Flow Per Share | - | -3.79 | 5.73 | 4.87 | -4.39 | Upgrade
|
| Gross Margin | 76.54% | 75.03% | 79.21% | 76.00% | 52.93% | Upgrade
|
| Operating Margin | 14.35% | 17.96% | 44.33% | 8.62% | -50.13% | Upgrade
|
| Profit Margin | 5.66% | 12.96% | 31.66% | 2.05% | -64.31% | Upgrade
|
| Free Cash Flow Margin | - | -23.60% | 21.12% | 30.17% | -111.49% | Upgrade
|
| EBITDA | 1,075 | 1,052 | 3,172 | 691.48 | -206.55 | Upgrade
|
| EBITDA Margin | 22.32% | 28.26% | 50.40% | 18.46% | -22.60% | Upgrade
|
| D&A For EBITDA | 383.54 | 383.54 | 382.3 | 368.76 | 251.55 | Upgrade
|
| EBIT | 691.16 | 668.96 | 2,790 | 322.72 | -458.11 | Upgrade
|
| EBIT Margin | 14.35% | 17.96% | 44.33% | 8.62% | -50.13% | Upgrade
|
| Effective Tax Rate | 38.57% | 16.38% | 12.74% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.